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ABSTRACT 
Consumption of fish/fish oil has been reported to modulate the symptoms in cardiovascular disease, inflammatory responses, 
cancer, and neurological disorders. The objective of this review is to provide therapeutic role of polyunsaturated fatty acids (PUFA) 
with practical evidences carried out in recent years. Literature studies were selected using the  Google, Pub Med and Medline 
database on the basis of the following criteria: (1) significance of omega-3-fatty acid in nutrition and disease (2) randomized 
controlled design, placebo controlled studies using Eicosapentaenoic acid and Docosahexaenoic acid. Imbalance in fatty acid 
composition is thought to be the major risk factor for the development and progression of various diseases. Omega-3 fatty acid up 
regulates anti-inflammatory and anti-apoptotic gene expression. It also competes with enzymes essential for ω-6 PUFA derived pro-
inflammatory eicosanoid mediators. In addition, it reduces blood pressure, angiogenesis process. Interactions of PUFA with signal 
transduction pathways reverse the symptoms associated with depression whereas transcription factors modulates tumor 
metabolism. Consumption of fatty fish/ fish oil is associated with reduced risk for cardiovascular disease, inflammatory responses, 
cancer and neurological disorders. 
Keywords: ω-3 polyunsaturated fatty acids, Eicosapentaenoic acid, Docosahexaenoic acid, biopharmaceuticals, health disorder. 
 
INTRODUCTION 
atty acids are chains of hydrocarbons with 
carboxylic acid (COOH) at one end and an methyl 
group at the other end. Human and mammalian 
system cannot place a double bond at the third carbon 
position or in the sixth carbon position from the methyl 
end or omega end of the fatty acid (FA) chain. For this 
reason, linoleic acid (LA, 18:2) and alpha- linolenic acid 
(ALA, 18:3) are called as essential fatty acids (EFA). 
Polyunsaturated fatty acids (PUFAs) include the family of 
ω-3 and ω-6 fatty acids. Omega-3 series are derived from 
ALA and omega-6 from linoleic acid. Alpha-linolenic acid is 
converted into long chain ω-3 PUFA such as 
Eicosapentaeonic acid (EPA, 20:5, ω-3) and 
Docosahexaenoic acid (DHA, 22:6, ω-3). Similarly, LA  can 
be sequentially converted via biosynthetic pathway into 
other ω -6 fatty acids i.e Gamma-linolenic acid (GLA, 18:3, 
ω−6), Arachidonic acid (AA, 20:4, ω−6) and Di-homo-
gamma-linolenic acid (DGLA, 20:3, ω-6). Since Burr and 
Burr’s1 discovery of  EFA namely ω-6 LA and  ω -3 ALA, the 
subject on PUFAs has opened to a better understanding 
of their role in public health and disease [Figure 1].  
Although mammalian cells cannot synthesize LA and ALA 
they can be formed by the introduction of double bonds 
(desaturation step) via ∆5 and ∆6 desaturase and by 
increasing the acyl chain (elongation) via elongases 
[Figure2]. Consequently, LA is converted to GLA by the 
action of ∆6 desaturase and GLA is elongated to form 
DGLA, the precursor of the 1 series prostaglandins (PGs). 
Dihomo-gamma-linolenic acid is further converted into 
AA (20:4, ω-6) by ∆6 desaturase. Arachidonic acid is the 
precursor of 2 series of PGs, thromboxanes, 4 series of 
Leukotrienes (LT). Using the same series of enzymes as 
those used to metabolize ω-6 PUFAs (elongases, ∆5 and ∆6 
desaturases), ALA is converted to EPA (20:5, ω-3) by ∆5 
and ∆6  desaturase. Eicosapentaenoic acid is the precursor 
of 3 series of PGs, 5 series of LT and resolvins. Since LA 
and ALA compete for the same set of enzymes abundant 
of one reduces the metabolism of the other. Under an 
ideal physiological ratio of 1:4, ∆5 and ∆6 desaturases and 
elongases have higher affinity to metabolize ω-3 over ω-6 
PUFAs. Eicosapentaenoic acid further gets converted to 
DHA by elongases and ∆6 desaturase respectively. Only 8-
20% of ALA is converted into EPA in humans, ALA to DHA 
is less or around 0.5-9%. This lower rate of conversion is 
unlikely to provide sufficient levels of EPA and DHA for 
normal health and therefore mammalian system is 
dependent on dietary sources rich in polyunsaturated 
fatty acid.  In recent years, tremendous work has been 
carried out worldwide to elucidate the therapeutic 
importance of PUFAs, in general, and omega-3-fatty acids, 
in particular, in human health care. This review gives 
compilation of theoretical and practical evidences 
published on this topic for the past five years for the 
benefit of scientific and unscientific society.   
 
Figure 1: Properties of omega-3-fatty acid 
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Figure 2: Biosynthetic pathway of polyunsaturated fatty 
acid and their mediators 
SOURCES OF PUFA 
Seaweeds and unicellular phytoplankton are the major 
sources of ω-3 FA (EPA & DHA). Marine fishes are 
enriched with long chain PUFA (LC-PUFA) as they 
consume phytoplankton and get transferred to different 
levels of species through food chain2 (table 1). Cold water 
oily fishes such as salmon, herring, mackerel and sardines 
are also rich in EPA & DHA. Oil from red and brown algae 
is a good source of ω-3 PUFA3. Breast milk comprises of 
all PUFAs essential for infant growth4. Linoleic acid and 
ALA are present in significant amounts in vegetable oils 
and in other natural sources5 (table 2 and table 3).  
Table 1 
Fish ⁄ sea food Gram to provide 1g EPA and DHA per day 
Fresh tuna 70–360 
Sardines 60–90 
Salmon 60–135 
Mackerel 60–250 
Herring 45–60 
Rainbow trout 90–105 
Halibut 90–225 
Cod 375–750 
Haddock 450 
Catfish 450–600 
Flounder 210 
Oyster (Pacific ⁄ 
eastern ⁄ farmed) 75 ⁄ 195 ⁄ 240 
Lobster 225 
Crab, Alaska King 255 
Shrimp 330 
Clam 375 
Scallop 525 
Amounts (g) of few sea fish foods which should be consumed to provide 
1 g EPA and DHA; Source: Ward & Singh (2005) 
Table 2 
Vegetables 
and oils                  
Fat content   
(g/100 g) 
EPA + 
DHA (g/ 
100 g) 
Fat content (EPA 
+ DHA) EPA + 
DHA (g 100 g) 
Eel 24.5 0.83 29.51 
Hering 17.8 2.72 6.54 
Sprat 16.6 3.23 5.14 
Tuna 15.5 3.37 4.6 
Salmon 13.6 2.86 4.76 
Mackerel 11.9 1.75 6.8 
Carp 4.8 0.3 16 
Sardine 4.5 1.39 3.24* 
Swordfish 4.4 1.79 2.45* 
Trout 2.7 0.59 4.58 
Halibut 1.7 0.51 3.33* 
Cod 0.6 0.18 3.33* 
Haddock 0.6 0.16 3.75* 
Lobster 1.9 0.2 9.5 
Shrimp 1.4 0.3 4.66 
Mussels 1.4 0.15 9.33 
Anchovy 2.3 0.5 4.6 
Sardine 13.9 2.44 5.7 
Table 3 
Fat content   
(g 100g)                   
ALA (g 
100g) 
Fat content 
⁄ ALA (g 
100g) 
Fat content   
(g 100g) 
Butter 83.2 1.2 69.3 
Lard 100 0.98 102.04 
Linseed oil 100 54.2 1.84 
Soybean oil 100 7.7 12.98 
Rapseed oil 100 9.15 10.93 
Walnut oil 100 13.5 7.40* 
Olive oil 100 0.86 6.25 
Vegetable oil 80 2.4 33.3 
Almonds 54.1 0.26 208.07 
Hazelnut 61.6 0.15 410.6 
Walnuts 62.5 6.8 9.19 
Kale 0.9 0.35 2.57* 
Lettuce 0.22 0.07 3.14* 
Parsley 0.36 0.12 3* 
Potato 0.11 0.02 5.5* 
Cauliflower 0.18 0.1 1.8* 
Spinach 0.3 0.13 2.31* 
White 
cabbage 0.2 0.09 2.22* 
Wheat bran 4.65 0.16 29.06 
Fat content ⁄ EPA + DHA (g 100 g) and fat content ⁄ ALA (g 100 g) raƟo of 
some various fish, marine products, vegetables and oils; Source: Sauci et 
al (1994) 
*Food which appears as perfect from the point of omega 3 content 
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OMEGA FATTY ACIDS AND NEUROLOGICAL DISORDERS 
There appears to be sufficient evidences on the 
importance of PUFAs in brain function. A preponderance 
of this research has focused on DHA, that is preferentially 
deposited in brain phospholipids and has been linked to 
Dementia, Parkinson disease, Alzheimer disease (AD), 
Huntington’s Disease, Cognition, Suicide, Depression, 
Bipolar disorders, Schizophrenia and Mood disorders, 
Anxiety, Aggression6-16 etc.  
Depression and Mental Disorders 
Interestingly, ω-3 PUFA has been reported to be effective 
against depressive disorders. Imbalance in FA 
composition is the leading cause of mood disorders. 
Docosahexaenoic acid helps in the maintenance of 
neuronal membrane stability and regulates the function 
of serotonin and dopamine transmission, the key 
components for depression.  
In a double blind (DB) intervention study, 
supplementation of 2.5g/day of ω-3 PUFA for two months 
significantly reduced depressive symptoms among elderly 
patients suffering from major depression/dysthymia and 
resulted in significant decrease in AA/EPA ratio in red 
blood cells membrane and improved phospholipid FA 
profile17. In a nine week randomized, masked, placebo-
controlled [PC] study, combination therapy (2gms 
containing a blend of 900mg EPA, 200mg DHA, and 
100mg other ω-3 fatty acids twice daily plus citalopram (a 
selective serotonin uptake inhibitor) displayed significant 
improvement in ameliorating signs and symptoms of 
major depression disorder in forty two subjects than 
monotherapy (2 grams olive oil per day plus citalopram) 
18. Evidences from randomized, DB, PC study suggests 
that compared to placebo, supplementation/diet 
enriched with ω-3 PUFA may protect elderly patients with 
mild cognitive impairment from cognitive decline and 
ameliorate depressive symptoms and the risk of 
progressing to dementia19-21. Supplementation of EPA ≥ 
60% of total EPA + DHA (200-2200 mg/d) was effective 
against primary depression22.  
Increased suicide risk is associated with lower intake of 
PUFA in Japanese women compared to men23. Lower 
levels of PUFA concentrations (DHA and AA) are seen in 
erythrocyte membranes of schizophrenia patients24. In a 
two DB, PC pilot studies on schizophrenia patients, EPA 
treatment benefited persons suffering from schizophrenia 
compared to DHA25. Supplementation of 1g/day of ω-3 
PUFA showed positive effect on the patients suffering 
from persistent depression26. According to a case study, 
proportion of ω-6/ ω-3 ratio, plasma DHA, HDL is 
associated with mental retardation in mentally retarded 
children in Korea27. 
Alzheimer disease  
Studies suggest that, apolipoprotein-E polymorphism is 
the major genetic risk factor for the development of 
sporadic Alzheimer’s disease28. Several epidemiological 
studies and clinical trials suggest that ω-3 PUFA in general 
and DHA in particular has emerged as a potential tool 
against Alzheimer’s disease.  
Docosatriens (10, 17s) also known as Neuroprotectin D1 
(NPD1) are conjugated triene structures derived from 
DHA (Figure 3). They possess immune-regulatory and 
neuroprotective properties8. Addition of nano molar 
concentration of DHA to primary co-cultures of human 
neurons and glial cells have resulted in 20-25% decrease 
in amyloid β (aβ) production, accompanied with NPD1 
biosynthesis and 50% decrease in apoptosis caused by aβ. 
This neuroprotective property is due to upregulation of 
anti-inflammatory and anti-apoptotic genes namely anti-
apoptotic Bcl-2 & Bcl- XL29.  
 
Figure 3: Neuroprotectin D1 biosynthesis and its function 
In a randomized DB, PC OmegAD study, dietary 
administration with either 1.7 g of DHA and 0.6 g EPA or 
placebo for 6 months to 174 AD patients resulted in 
downregulation of genes involved in inflammation 
regulation, neurodegeneration and significantly improved 
plasma EPA & DHA levels30.Evidences from randomized, 
DB, PC study suggests that compared to placebo, 
supplementation/diet enriched with ω-3 PUFA may 
protect elderly patients with mild cognitive impairment 
from cognitive decline and ameliorate depressive 
symptoms and the risk of progressing to dementia. 
However, supplementation of LC-PUFA showed no 
benefit on cognitive function in cognitively healthy older 
people and in patients with mild to moderate Alzheimer 
disease31- 33. Addition of 5-20 µM DHA inhibits Aβ 
fibrillation under in vitro and in vivo conditions. This 
function attributes to anti-amyloid properties of 
docosahexaenoic acid. Overall these results suggest that 
DHA & EPA may be used as a potential therapeutic agent 
against mild cognitive impairment and ALZ disease34-36. 
Conversely, compared to placebo, supplementation of 
algal DHA (2g/d) for 18 months did not slow the rate of 
cognitive and functional decline in patients with mild to 
moderate Alzheimer disease37. 
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OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR 
DISEASES (CVD) 
Cardiovascular disease is a leading cause of mortality and 
morbidity worldwide today. Decreased risk of CVD was 
observed in Greenland Eskimos who consumed fish 
enriched with ω-3 fatty acids38, 39. According to the World 
Health Organization recommendations, the optimal ratio 
of ω-6 to ω-3 PUFAs is 5-8:1. At this ratio, consumption of 
LC-PUFA in food or in the form of drugs can act as potent 
antagonists to ω-6 PUFA synthesis and acts as membrane 
protectors, inhibiting the synthesis of AA from linoleic 
acid and competing with AA for the binding to cell 
membrane phospholipids40, 41.  
Cardiovascular protective nature of LC-PUFA is attributed 
to its property of reducing cholesterol and thus the risk of 
myocardial infarcation (MI), serum triglyceride in blood 
serum level of hyperglycemia patients, decreasing plasma 
triacylglyceride, blood pressure, platelet aggregation, 
inflammation, easing blood circulation42-48. Supporting 
evidences followed by expanded interest on omega-3-
index indicates that persons having omega-3-index <4% 
are at a tenfold higher risk to CVD than individuals with 
an omega-3-index >8%49. In a case control study, intake of 
ω-3 PUFA significantly decreased plasma lipid 
hydroperoxide level and thereby reduced the level of 
oxidative damage among elderly patients with MCI50. 
Addition of EPA and DHA (50-300µM) helps in down 
regulating cholesterol absorption genes such as NPC1L1 
and its protein expression in human enterocytes in vitro 
51. Supplementation of ω-3 PUFA showed beneficial 
effects in the prevention of atrial fibrillation recurrence52, 
53. Conversely, in a randomized, DB, multicentre study, 
treatment with PUFA did not reduce recurrent atrial 
fibrillation54, 55.Treatment with DHA (200mg/kg) 
attenuated the expression of TNF-α-induced vascular cell 
adhesion molecule 1 (VCAM-1) and NF-κB activation in 
TNF-α-treated human aortic endothelial and thereby 
contributing to the prevention of atherosclerosis in 
mice56.  
OMEGA -3 FATTY ACIDS AND CELL PROLIFERATION 
Ecological studies have shown that high per capita fish 
consumption is correlated with a lower incidence of 
cancer in the population57. Indeed, epidemiological 
studies suggest that Eskimos and Alaskans who consume 
large quantities of fish have a low risk for cancer58.  
Several molecular mechanisms whereby ω-3 PUFA 
potentially inhibits carcinogenesis have been proposed59.  
These mechanisms include  
1) Inhibition of  eicosanoids  derived  AA  
2) Modulation of transcription factor, gene 
expression and signal transduction which leads 
to changes in tumor metabolism, proliferation  
and differentiation 
3) Changes in estrogen metabolism 
4) Decreasing  the  levels of free radicals and 
reactive oxygen species 
5) Expression of apoptotic inducing  Bax, p53 
proteins 
6) Reduction in angiogenesis process 
Prostate cancer is the most commonly diagnosed cancer 
and is one of the leading cause of death among men in 
America60. Addition of ALA/DHA to gastric epithelial cells 
inhibited oxidative stress induced cellular events such as 
glucose oxidase mediated apoptosis, DNA fragmentation, 
induction of p53 and Bax proteins
61.Omega-3-fattyacids 
post-transcriptionally regulates over expression of Zeste 
Homologue2 (EZH2), a polycomb group protein in breast 
cancer cells62.Recently EPA has shown to be beneficial in 
anti-cachexia therapy63. In a prospective cohort study on 
Shanghai women fed with diet lower in ω-3 PUFA suggest 
that, two fold increase in breast cancer risk in women 
compared to subjects consuming diets enriched with ω-3 
PUFA64. Intake of ω-3 PUFA from fish has inverse relation 
with postmenopausal breast cancer risk65.  
Recent studies reports that, LC-PUFA may be used as a 
therapeutic agent for the chemoprevention of human 
pancreatic cancer66, 67. Increase intake of food and 
supplements rich in PUFA is associated with reduced risk 
of endometrial cancer68. Docosahexaenoic acid inhibits 
the process of tumor establishment69. Furthermore, ω-3 
PUFA has shown to reduce angiogenesis, decreases 
nuclear factor–κβ (NF-κβ) activation70-72. Increasing body 
of evidence has shown that, supplementation of DHA 
upregulates syndecan-1 (SDC-1, a tumor suppressor 
molecule), which induces apoptosis through activation of 
PPARγ and inhibits MEK/Erk/Bad signaling under in vitro 
and in vivo conditions73, 74. 
OMEGA-3 FATTY ACIDS AND RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is an autoimmune disease that 
causes chronic inflammation of the joints. In vitro study 
test on various PUFAs showed that ω-3 PUFAs not ω -6 
PUFAs are able to markedly decrease mRNA expression 
level of key initial cartilage degrading proteinases 
(ADAMTS-4& -5) and Cox-2  and  also reduced the levels 
of inflammatory cytokines, TNF-α, IL-1α and IL-1β75. 
Molecular mechanism by which ω-3 PUFAs may help to 
reduce the symptoms of RA are as follows76: 
1. Compete with enzymes essential for ω-6 PUFA 
derived pro-inflammatory eicosanoid mediators 
2. Reduce the gene expression of Cox-2 enzyme, 
cytokines, TNF-α, IL-1α, IL-1β 
3. Reduce the gene expression of key initial cartilage 
degrading proteinases such as ADAMTS-4 and -5, 
matrix metalloproteinases -3 and -13 
The above supporting evidences indicate that, 
supplementation of EPA helps in the reduction of pro-
inflammatory agents which plays a key orchestral role in 
causing inflammation in rheumatoid arthritis.  
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CONCLUSION 
Polyunsaturated fatty acids are the precursors to a variety 
of potential mediators with diverse biological function. 
However, molecular mechanisms behind these specific 
biologically active molecules in various cells and tissues 
processes still remain unclear. Furthermore, when these 
fatty acids are incorporated into the cell membrane they 
tend to alter its properties including composition of fatty 
acids, fluidity, that in turn helps in the modulation of the 
number and affinity of various receptors, ligands to their 
respective growth factors, co-factors, enzymes, 
hormones, peptides and proteins. Yet another action is 
their ability to form complexes with other biologically 
active molecules such as aspirin. Formation of such 
complexes between PUFAs and other biologically active 
molecules could help in the synthesis of newly formed 
derivatives like NPD1 that in turn shows varied biological 
actions useful to our body. Elucidating the role of 
enzymes in the pathway, formation of such biologically 
active complexes is not only interesting but also 
challenging since such complexes may form the basis of 
understanding certain less well understood physiological 
and pathological processes. Furthermore, studies have to 
be carried out on pro and anticancer, anti-inflammatory 
association of ω-3 fatty acids. Synthesis of synthetic and 
stable potent eicosanoids such as LXs, resolvins, and 
NPD1 would help in amelioration of several inflammatory 
responses. In view of their diverse actions, PUFAs may lay 
a strong foundation for the formulation of many 
pharmaceutical  drugs. 
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